相关实验视频

Updated: Jun 25, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

与免疫相关的不良事件与免疫检查点抑制剂的疗效之间的相关性

Taito Fukushima¹, Satoshi Kobayashi¹, Makoto Ueno¹

¹Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.

Japanese journal of clinical oncology

|May 21, 2024

概括

免疫检查点抑制剂 (ICI) 可以引起与免疫相关的不良事件 (irAEs). 虽然irAEs可能表明对ICI治疗的反应更好,但它们对患者结果的预测价值仍然不清楚.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

针对CTLA-4和PD-1/PD-L1的免疫检查点抑制剂 (ICI) 已经改变了癌症治疗.
ICI可能导致与常规化疗副作用不同的免疫相关不良事件 (irAEs).
由于免疫系统的激活,irAEs会影响各种器官,包括结肠,肝脏,肺和皮肤.

研究的目的:

对接受ICI治疗的患者中IRE和临床结果之间的关联进行检查的关键研究进行审查.
探索IREs对ICI治疗反应的潜在预测价值.
在ICI疗效的背景下,巩固目前对irAEs的理解.

主要方法:

对最近的回顾性研究和关键研究进行系统审查.
文献分析,重点关注irAE发展与临床疗效之间的联系.
检查研究IREs,发病时间和免疫抑制治疗的研究.

主要成果:

新出现的证据表明,IRAE与ICI反应的改善之间存在潜在的相关性.
对于ICI治疗结果的irAEs的精确预测值需要进一步调查.
目前的研究主要集中在irAE的特征和管理策略上.

结论:

与免疫相关的不良事件可以作为免疫检查点抑制剂治疗增强反应的生物标志物.
进一步的研究至关重要,以阐明irAEs在确定患者结果中的预测作用.
了解IRAE与ICI疗效之间的关系对于优化癌症治疗策略至关重要.

关键词:

它们是Atezolizumab.有效性有效性有效性.免疫检查点抑制剂免疫检查点抑制剂与免疫相关的不良事件.一个不错的例子是 ipilimumab.这就是尼沃卢马布 (nivolumab).这就是Pembrolizumab.

更多相关视频

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.